Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.19 USD | +0.97% | -1.70% | -62.77% |
May. 31 | Verve Therapeutics Names Troy Lister Chief Scientific Officer | MT |
May. 31 | Verve Therapeutics, Inc. Announces Executive Changes | CI |
Business Summary
Number of employees: 255
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceutical
100.0
%
| 2 | 100.0 % | 12 | 100.0 % | +505.77% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 2 | 100.0 % | 12 | 100.0 % | +505.77% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Sekar Kathiresan
FOU | Founder | 52 | 17-12-31 |
Allison Dorval
DFI | Director of Finance/CFO | 48 | 21-11-28 |
Andrew Ashe
PSD | President | 57 | 18-07-31 |
Jason Politi
CTO | Chief Tech/Sci/R&D Officer | 47 | 21-01-31 |
Richard Falzone
CTO | Chief Tech/Sci/R&D Officer | 50 | 21-03-31 |
Joan Nickerson
ADM | Chief Administrative Officer | 56 | 21-03-31 |
Troy Lister
CTO | Chief Tech/Sci/R&D Officer | - | 22-04-30 |
Andrew Bellinger
CTO | Chief Tech/Sci/R&D Officer | 46 | 19-09-30 |
Fred Fiedorek
CTO | Chief Tech/Sci/R&D Officer | 69 | 23-09-17 |
Andrew Sheely
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Burt Adelman
FOU | Founder | 71 | 17-12-31 |
Lonnel Coats
BRD | Director/Board Member | 58 | 22-08-07 |
Michael MacLean
BRD | Director/Board Member | 58 | 21-04-30 |
Sheila Mikhail
BRD | Director/Board Member | 57 | 21-03-31 |
Krishna Yeshwant
BRD | Director/Board Member | 45 | 18-07-31 |
Alexander Cumbo
BRD | Director/Board Member | 53 | 22-06-08 |
Sekar Kathiresan
FOU | Founder | 52 | 17-12-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 83,965,493 | 77,497,248 ( 92.30 %) | 0 | 92.30 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-62.77% | 436M | |
+43.36% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+0.04% | 12.16B | |
+25.12% | 12.21B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- VERV Stock
- Company Verve Therapeutics, Inc.